Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 717

1.

Chemically induced aneuploidy in germ cells. Part II of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Pacchierotti F, Masumura K, Eastmond DA, Elhajouji A, Froetschl R, Kirsch-Volders M, Lynch A, Schuler M, Tweats D, Marchetti F.

Mutat Res. 2019 Dec;848:403023. doi: 10.1016/j.mrgentox.2019.02.004. Epub 2019 Mar 20.

PMID:
31708072
2.

Role of aneuploidy in the carcinogenic process: Part 3 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Tweats D, Eastmond DA, Lynch AM, Elhajouji A, Froetschl R, Kirsch-Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M.

Mutat Res. 2019 Nov;847:403032. doi: 10.1016/j.mrgentox.2019.03.005. Epub 2019 Mar 29.

PMID:
31699349
3.

Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases.

Lynch AM, Eastmond D, Elhajouji A, Froetschl R, Kirsch-Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M, Tweats D.

Mutat Res. 2019 Nov;847:403025. doi: 10.1016/j.mrgentox.2019.02.006. Epub 2019 Mar 2.

PMID:
31699346
4.

High information content assays for genetic toxicology testing: A report of the International Workshops on Genotoxicity Testing (IWGT).

Dertinger SD, Totsuka Y, Bielas JH, Doherty AT, Kleinjans J, Honma M, Marchetti F, Schuler MJ, Thybaud V, White P, Yauk CL.

Mutat Res. 2019 Nov;847:403022. doi: 10.1016/j.mrgentox.2019.02.003. Epub 2019 Feb 21.

PMID:
31699343
5.

Application of the adverse outcome pathway framework to genotoxic modes of action.

Sasaki JC, Allemang A, Bryce SM, Custer L, Dearfield KL, Dietz Y, Elhajouji A, Escobar PA, Fornace AJ Jr, Froetschl R, Galloway S, Hemmann U, Hendriks G, Li HH, Luijten M, Ouedraogo G, Peel L, Pfuhler S, Roberts DJ, Thybaud V, van Benthem J, Yauk CL, Schuler M.

Environ Mol Mutagen. 2019 Oct 11. doi: 10.1002/em.22339. [Epub ahead of print]

PMID:
31603995
6.

Effects of nationwide implementation of work-related medical rehabilitation in Germany: propensity score matched analysis.

Bethge M, Markus M, Streibelt M, Gerlich C, Schuler M.

Occup Environ Med. 2019 Dec;76(12):913-919. doi: 10.1136/oemed-2019-106065. Epub 2019 Oct 8.

PMID:
31594839
7.

College attendance type and subsequent alcohol and marijuana use in the U.S.

Jang JB, Schuler MS, Evans-Polce RJ, Patrick ME.

Drug Alcohol Depend. 2019 Sep 22;204:107580. doi: 10.1016/j.drugalcdep.2019.107580. [Epub ahead of print]

PMID:
31585359
8.

Yoga intervention and reminder e-mails for reducing cancer-related fatigue - a study protocol of a randomized controlled trial.

Zetzl T, Schuler M, Renner A, Jentschke E, van Oorschot B.

BMC Psychol. 2019 Sep 18;7(1):64. doi: 10.1186/s40359-019-0339-3.

9.

Capillary electrophoresis with dual detection UV/C4D for monitoring myrosinase-mediated hydrolysis of thiol glucosinolate designed for gold nanoparticle conjugation.

Claude B, Cutolo G, Farhat A, Zarafu I, Ionita P, Schuler M, Tatibouët A, Morin P, Nehmé R.

Anal Chim Acta. 2019 Nov 28;1085:117-125. doi: 10.1016/j.aca.2019.07.043. Epub 2019 Jul 24.

PMID:
31522725
10.

Current State of Sarcoma Care in Germany: Results of an Online Survey of Physicians.

Eichler M, Richter S, Hohenberger P, Kasper B, Andreou D, Heidt V, Bornhäuser M, Schmitt J, Schuler MK.

Oncol Res Treat. 2019;42(11):589-598. doi: 10.1159/000502758. Epub 2019 Sep 11.

PMID:
31509840
11.

Question prompts to empower cancer patients: results of a randomized controlled trial.

Zetzl T, Mann D, Gruner S, Schuler M, Jentschke E, Neuderth S, Roch C, van Oorschot B.

Support Care Cancer. 2019 Sep 10. doi: 10.1007/s00520-019-05036-0. [Epub ahead of print]

PMID:
31502228
12.

The lipid metabolism in thraustochytrids.

Morabito C, Bournaud C, Maës C, Schuler M, Aiese Cigliano R, Dellero Y, Maréchal E, Amato A, Rébeillé F.

Prog Lipid Res. 2019 Oct;76:101007. doi: 10.1016/j.plipres.2019.101007. Epub 2019 Sep 6. Review.

PMID:
31499096
13.

Fast and Noninvasive Diagnosis of Cervical Cancer by Coherent Anti-Stokes Raman Scattering.

Aljakouch K, Hilal Z, Daho I, Schuler M, Krauß SD, Yosef HK, Dierks J, Mosig A, Gerwert K, El-Mashtoly SF.

Anal Chem. 2019 Nov 5;91(21):13900-13906. doi: 10.1021/acs.analchem.9b03395. Epub 2019 Sep 17.

PMID:
31483624
14.

[Duration and variation of the ethics approval process in Germany - an example from a non-interventional study with 44 participating centers].

Eichler M, Schmitt J, Schuler MK.

Z Evid Fortbild Qual Gesundhwes. 2019 Oct;146:15-20. doi: 10.1016/j.zefq.2019.07.006. Epub 2019 Aug 29. German.

PMID:
31473073
15.

Primary cell-based phenotypic assays to pharmacologically and genetically study fibrotic diseases in vitro.

Weigle S, Martin E, Voegtle A, Wahl B, Schuler M.

J Biol Methods. 2019 Jun 3;6(2):e115. doi: 10.14440/jbm.2019.285. eCollection 2019.

16.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
17.

The coupling of localised, vibrational modes - Probing OH-bands of organic molecules via a two dimensional Numerov approach.

Schuler MJ, Henn R, Kirchler CG, Schlapp-Hackl I, Huck CW, Hofer TS.

Spectrochim Acta A Mol Biomol Spectrosc. 2020 Jan 5;224:117377. doi: 10.1016/j.saa.2019.117377. Epub 2019 Jul 23.

PMID:
31400743
18.

Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.

Bardia A, Gounder M, Rodon J, Janku F, Lolkema MP, Stephenson JJ, Bedard PL, Schuler M, Sessa C, LoRusso P, Thomas M, Maacke H, Evans H, Sun Y, Tan DSW.

Oncologist. 2019 Aug 8. pii: theoncologist.2019-0297. doi: 10.1634/theoncologist.2019-0297. [Epub ahead of print]

PMID:
31395751
19.

Nutrients influence the multi-trophic impacts of an invasive species unaffected by native competitors or predators.

Hintz WD, Schuler MS, Jones DK, Coldsnow KD, Stoler AB, Relyea RA.

Sci Total Environ. 2019 Jul 31;694:133704. doi: 10.1016/j.scitotenv.2019.133704. [Epub ahead of print]

PMID:
31394331
20.

Substrate-specificity of cytochrome P450-mediated detoxification as an evolutionary strategy for specialization on furanocoumarin-containing hostplants: CYP6AE89 in parsnip webworms.

Calla B, Wu WY, Dean CAE, Schuler MA, Berenbaum MR.

Insect Mol Biol. 2019 Aug 8. doi: 10.1111/imb.12612. [Epub ahead of print]

PMID:
31393031
21.

Bandwidth renormalization due to the intersite Coulomb interaction.

In 't Veld Y, Schüler M, Wehling TO, Katsnelson MI, van Loon EGCP.

J Phys Condens Matter. 2019 Nov 20;31(46):465603. doi: 10.1088/1361-648X/ab36fe. Epub 2019 Jul 30.

PMID:
31362270
22.

Baseline health status and setting impacted minimal clinically important differences in COPD: an exploratory study.

Alma H, de Jong C, Jelusic D, Wittmann M, Schuler M, Kollen B, Sanderman R, Kocks J, Schultz K, van der Molen T.

J Clin Epidemiol. 2019 Jul 27;116:49-61. doi: 10.1016/j.jclinepi.2019.07.015. [Epub ahead of print]

23.

[Treatment of pain in people with dementia].

Schuler M.

Z Gerontol Geriatr. 2019 Oct;52(6):607-622. doi: 10.1007/s00391-019-01578-4. Epub 2019 Jul 25. German.

PMID:
31346680
24.

Thresholds for clinically important deterioration versus improvement in COPD health status: results from a randomised controlled trial in pulmonary rehabilitation and an observational study during routine clinical practice.

Alma HJ, de Jong C, Jelusic D, Wittmann M, Schuler M, Sanderman R, Schultz K, Kocks J, van der Molen T.

BMJ Open. 2019 Jun 28;9(6):e025776. doi: 10.1136/bmjopen-2018-025776.

25.

[Postoperative mobilization after total hip arthroplasty : Measured by Fitbit activity trackers].

Doppelbauer M, Schüler M, Sauter D.

Orthopade. 2019 Jun 27. doi: 10.1007/s00132-019-03768-9. [Epub ahead of print] German.

PMID:
31250078
26.

Exam Wrapper Use and Metacognition in a Fundamentals Course: Perceptions and Reality.

Schuler MS, Chung J.

J Nurs Educ. 2019 Jul 1;58(7):417-421. doi: 10.3928/01484834-20190614-06.

PMID:
31242311
27.

A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.

Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M.

Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199.

28.

Changing Roles, Changing Perspectives-Vulnerability as a Patient.

Schuler M.

J Patient Exp. 2019 Mar;6(1):5-6. doi: 10.1177/2374373518769662. Epub 2018 Apr 25.

29.

Nanodiscs as a New Tool to Examine Lipid-Protein Interactions.

Denisov IG, Schuler MA, Sligar SG.

Methods Mol Biol. 2019;2003:645-671. doi: 10.1007/978-1-4939-9512-7_25.

PMID:
31218635
30.

More than pills: alternative adjunct therapies to improve comfort in hospitalised patients.

Moore M, Schuler M, Wilson S, Whisenhunt M, Adams A, Leiker B, Butler T, Shankweiler C, Jones M, Gibson C.

BMJ Open Qual. 2019 May 9;8(2):e000506. doi: 10.1136/bmjoq-2018-000506. eCollection 2019.

31.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC.

Lung Cancer. 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.

32.

Sexual minority disparities in opioid misuse, perceived heroin risk and heroin access among a national sample of US adults.

Schuler MS, Dick AW, Stein BD.

Drug Alcohol Depend. 2019 Aug 1;201:78-84. doi: 10.1016/j.drugalcdep.2019.04.014. Epub 2019 Jun 7.

PMID:
31200278
33.

The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer.

Pastille E, Wasmer MH, Adamczyk A, Vu VP, Mager LF, Phuong NNT, Palmieri V, Simillion C, Hansen W, Kasper S, Schuler M, Muggli B, McCoy KD, Buer J, Zlobec I, Westendorf AM, Krebs P.

Mucosal Immunol. 2019 Jul;12(4):990-1003. doi: 10.1038/s41385-019-0176-y. Epub 2019 Jun 5.

34.

Pre-post changes in main outcomes of medical rehabilitation in Germany: protocol of a systematic review and meta-analysis of individual participant and aggregated data.

Schuler M, Murauer K, Stangl S, Grau A, Gabriel K, Podger L, Heuschmann PU, Faller H.

BMJ Open. 2019 Jun 1;9(5):e023826. doi: 10.1136/bmjopen-2018-023826.

35.

Model assisted analysis of the hepatic arterial buffer response during ex vivo porcine liver perfusion.

Becker D, Hefti M, Schuler M, Bautista Borrego L, Hagedorn C, Muller X, Graf R, Dutkowski P, Tibbitt M, Onder C, Clavien PA, Eshmuminov D, Rudolf von Rohr P.

IEEE Trans Biomed Eng. 2019 May 28. doi: 10.1109/TBME.2019.2919413. [Epub ahead of print]

PMID:
31150329
36.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N.

Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.

37.

Human lung fibroblast-to-myofibroblast transformation is not driven by an LDH5-dependent metabolic shift towards aerobic glycolysis.

Schruf E, Schroeder V, Kuttruff CA, Weigle S, Krell M, Benz M, Bretschneider T, Holweg A, Schuler M, Frick M, Nicklin P, Garnett JP, Sobotta MC.

Respir Res. 2019 May 9;20(1):87. doi: 10.1186/s12931-019-1058-2.

38.

Empathy in pedophilia and sexual offending against children: A multifaceted approach.

Schuler M, Mohnke S, Amelung T, Dziobek I, Lemme B, Borchardt V, Gerwinn H, Kärgel C, Kneer J, Massau C, Pohl A, Tenbergen G, Weiß S, Wittfoth M, Waller L, Beier KM, Walter M, Ponseti J, Schiffer B, Kruger THC, Walter H.

J Abnorm Psychol. 2019 Jul;128(5):453-464. doi: 10.1037/abn0000412. Epub 2019 May 2.

PMID:
31045397
39.

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.

Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, Kopp HG, Mayer F, Haag GM, Luley K, Lindig U, Schmiegel W, Pohl M, Stoehlmacher J, Folprecht G, Probst S, Prasnikar N, Fischbach W, Mahlberg R, Trojan J, Koenigsmann M, Martens UM, Thuss-Patience P, Egger M, Block A, Heinemann V, Illerhaus G, Moehler M, Schenk M, Kullmann F, Behringer DM, Heike M, Pink D, Teschendorf C, Löhr C, Bernhard H, Schuch G, Rethwisch V, von Weikersthal LF, Hartmann JT, Kneba M, Daum S, Schulmann K, Weniger J, Belle S, Gaiser T, Oduncu FS, Güntner M, Hozaeel W, Reichart A, Jäger E, Kraus T, Mönig S, Bechstein WO, Schuler M, Schmalenberg H, Hofheinz RD; FLOT4-AIO Investigators.

Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.

PMID:
30982686
40.

Depression Subtypes in Persons with or at Risk for Symptomatic Knee Osteoarthritis.

Rathbun AM, Schuler MS, Stuart EA, Shardell MD, Yau MS, Gallo JJ, Ryan AS, Hochberg MC.

Arthritis Care Res (Hoboken). 2019 Apr 5. doi: 10.1002/acr.23898. [Epub ahead of print]

PMID:
30951261
41.

Diverted Natural Lossen-type Rearrangement for Bioconjugation through in Situ Myrosinase-Triggered Isothiocyanate Synthesis.

Fredy JW, Cutolo G, Poret B, Nehmé R, Hubert-Roux M, Gandolfo P, Castel H, Schuler M, Tatibouët A, Sabot C, Renard PY.

Bioconjug Chem. 2019 May 15;30(5):1385-1394. doi: 10.1021/acs.bioconjchem.9b00153. Epub 2019 Apr 16.

PMID:
30933500
42.

Intrasplenic Pancreatic Pseudocyst after Chemoradiation of a Pancreatic Adenocarcinoma Mimicking Progressive Disease: A Case Report and Review of the Literature.

Benter T, Roehr O, Moser L, Kiewe P, Hentschel L, Platzek I, Schuler MK.

Case Rep Oncol Med. 2019 Feb 14;2019:5808714. doi: 10.1155/2019/5808714. eCollection 2019.

43.

Substance use behaviors and the timing of family formation during young adulthood.

Jang BJ, Patrick ME, Schuler MS.

J Fam Issues. 2018 Apr;39(5):1396-1418. doi: 10.1177/0192513X17710285. Epub 2017 May 19.

44.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.

Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1569-1579. doi: 10.1007/s00432-019-02862-x. Epub 2019 Feb 19.

45.

Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer.

Wiesweg M, Mairinger F, Reis H, Goetz M, Walter RFH, Hager T, Metzenmacher M, Eberhardt WEE, McCutcheon A, Köster J, Stuschke M, Aigner C, Darwiche K, Schmid KW, Rahmann S, Schuler M.

Ann Oncol. 2019 Apr 1;30(4):655-657. doi: 10.1093/annonc/mdz049. No abstract available.

PMID:
30753264
46.

Differences in Substance Use Disparities Across Age Groups in a National Cross-Sectional Survey of Lesbian, Gay, and Bisexual Adults.

Schuler MS, Stein BD, Collins RL.

LGBT Health. 2019 Feb/Mar;6(2):68-76. doi: 10.1089/lgbt.2018.0125. Epub 2019 Feb 8.

47.

Lymph Node Involvement and the Surgical Treatment of Thymic Epithelial and Neuroendocrine Carcinoma.

Cheufou DH, Valdivia D, Puhlvers S, Fels B, Weinreich G, Taube C, Theegarten D, Stuschke M, Schuler M, Hegedus B, Stamatis G, Aigner C.

Ann Thorac Surg. 2019 Jun;107(6):1632-1638. doi: 10.1016/j.athoracsur.2019.01.006. Epub 2019 Feb 2.

PMID:
30721691
48.

Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.

Guberina M, Eberhardt W, Stuschke M, Gauler T, Aigner C, Schuler M, Stamatis G, Theegarten D, Jentzen W, Herrmann K, Pöttgen C.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1439-1447. doi: 10.1007/s00259-019-4270-x. Epub 2019 Feb 1.

PMID:
30710323
49.

The impact of disease-specific fears on outcome measures of pulmonary rehabilitation in patients with COPD.

Reijnders T, Schuler M, Wittmann M, Jelusic D, Troosters T, Janssens W, Stenzel NM, Schultz K, von Leupoldt A.

Respir Med. 2019 Jan;146:87-95. doi: 10.1016/j.rmed.2018.12.004. Epub 2018 Dec 13.

PMID:
30665524
50.

Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.

Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T.

Int J Cardiol. 2019 Apr 1;280:163-175. doi: 10.1016/j.ijcard.2019.01.038. Epub 2019 Jan 11.

PMID:
30661849

Supplemental Content

Loading ...
Support Center